Skip to content

Author

N. Tezcan

We have 3 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract PR005: The basal cell state maintains pancreatic cancers by controlling an immunosuppressive cell circuit

Intratumoral heterogeneity is a defining feature of pancreatic ductal adenocarcinoma (PDAC), yet how distinct malignant cell states contribute to tumor behavior and stromal diversity in situ remains poorly understood. PDAC contains recurrent classical and basal states, with basal-dominant tumors associated with aggre...

Kate Ryan, A. Singhal, Samuel A. Rose et al. · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations
Open access Aug 2026

Evolutionarily conserved epigenetic regulation of transcriptional cell states during vertebrate pancreatic tumorigenesis.

These findings suggest a highly conserved role for HDAC9 and class IIA HDACs in vertebrate pancreatic tumorigenesis and may lead to new strategies for reactivating (normal acinar/epithelial) differentiation programs to intercept and treat PDAC.

Somer Matar, Sandra Blázquez-Araguás, Andrea Diéguez-Docampo et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.